Universal Ibogaine Inc (TSX-V:IBO) (UI) has appointed Julie Dumouchel to lead the design, planning and execution of the clinical trials and projects related to the company’s ibogaine treatment protocol.
As Director of Clinical Trials, Dumouchel will spearhead UI’s planned clinical trial with Health Canada to prove the safety and efficacy of ibogaine for the disruption of opioid addiction, said the life sciences company.
READ: Universal Ibogaine partners with Osoyoos Indian Band for ibogaine-centered detox clinic
"We welcome Julie to our team, and look forward to her guidance as we continue to work with our CRO research partners to finalize our Clinical Trial Application for Health Canada. This announcement demonstrates we are making progress towards our CTA and (are) confident in our path forward," Nick Karos, UI CEO said in a statement.
UI owns the global licensing rights for the ibogaine treatment protocol developed by Dr Alberto Sola, a UI board member and one of the founders of the Clear Sky Recovery Clinic, which has operated an addiction treatment center in Cancun, Mexico since 2007. Sola has safely administered over 3,700 ibogaine treatments, more than any other doctor in the world.
Dumouchel brings 25 years of experience in the pharmaceutical industry, where she has held various clinical research roles, developing a deep understanding of the drug development process.
“She is passionate about clinical operations and the drug development process. Her experience leading strong research teams to advance clinical trials while navigating changing regulations will augment UI's planned business platforms of drug development and clinical service delivery,” the company said.
UI has a mission to demonstrate the safety and efficacy of its ibogaine-based drug detox protocol through a planned Canadian Clinical Trial, and ultimately to utilize that protocol globally through future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre in Winnipeg, Manitoba that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way addiction is treated in order to improve the lives of individuals and families affected by addiction.
Contact the author at jon.hopkins@proactiveinvestors.com